anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a compound Chinese medicinal extract composition and a preparing method thereof. The composition comprises a composite unit A and a composite unit B which are extracted and separated Chuanxiong rhizome, safflower, peach seed, red peony root, bitter orange and bupleurum root. Extract powder of each composite unit is obtained by a method of spray drying or freeze drying or vacuum drying, and the extract powder is combined to form the Chinese medicinal extract composition which comprises 1 to 5g of composite element A and 1.5 to 5g of composite element B, and the composition comprises the active components: 15% to 40% of paeoniflorin compound and 15% to 40% of flavonoid compound. The composition can obviously reduce the contents of total cholesterol and low-density lipoprotein cholesterol in rats of hyperlipidemia and can be used for preparing medicines for preventing and treating high blood fat and cholesterol as well as cardiovascular and cerebrovascular diseases. The composition can be prepared into oral medicinal liquid, granules, tablets, capsules and other oral preparations. Compared with the traditional compound, the present invention has the advantages of definite prescription, stable technology, conspicuous curative effect, etc.
A method for preventing the pyo-inflammatory complications after surgery in lungs and pleura provides for the use of the broad spectrum antibiotic. The first dose is administered prior to the beginning of the surgery. Intraoperatively, the soft tissues are treated with 5% solution of Betadine. Three broad spectrum antibiotics are used for 7 days: Amicacin 1.0 g, Ceftriaxon 1.0 g, and Levofoxacin 0.8 g followed by the specific antibiotic selected after the assessment of the sensitivity of the plated bacteria. Intraoperatively, the soft tissues are treated by Ceftriaxon 2.0 g in drops. The pleural cavity is sanitized mechanically and with Cyprofloxacin solution. The stump of the bronchus is treated with 0.5 g Tienam (in powder). Finally, the pleurization of the stump is performed.
PURPOSE:To obtain the titled homogeneous drug preparation soluble remarkably rapidly compared with the conventional preparation, by dissolving chloramphenicol in an organic solvent, spraying the solution to water-soluble powder, and drying the product. CONSTITUTION:A water-soluble powder (e.g. sucrose, glucose, dextrin, etc.) is sprayed with a solution prepared by dissolving a chloramphenicol compound in an anhydrous or hydrated organic solvent (e.g. ethanol, methanol, methylene chloride, etc.), and the product is dried to obtain the objective preparation. A remarkably rapid-dissolving drug preparation can be prepared by the above process. Furthermore, a homogeneous preparation free from the defects such as the local deviation and classification of chloramphenicol compound inevitable in the mixing and pulverization process can be obtained.
A device, such as a computing device or a surgical device, may receive surgical operation data associated with a surgical operation. Based on the surgical operation data, a device may identify a surgical device to be used for a surgical operation and/or one or more surgical steps associated with a surgical operation. Based on the identified surgical device, the one or more surgical steps, and/or the surgical operation data, a device may determine an allowable operation range controlling a surgical device for a surgical procedure. A device may receive an adjustment input configuration to control a surgical device for a surgical step. A device may determine whether the adjustment input configuration is outside of the determined allowable operation range. Based on a determination that the adjustment input configuration is outside of the determined allowable operation range, a device may block the adjustment input configuration to control a surgical device.
There have been no reports of significant overdose with DEXILANT. Multiple doses of DEXILANT 120 mg and a single dose of DEXILANT 300 mg did not result in death or other severe adverse events. However, serious adverse events of hypertension have been reported in association with twice daily doses of DEXILANT 60 mg. Nonserious adverse reactions observed with twice daily doses of DEXILANT 60 mg include hot flashes, contusion, oropharyngeal pain, and weight loss. Dexlansoprazole is not expected to be removed from the circulation by hemodialysis.

In the event of over-exposure, treatment should be symptomatic and supportive.

If over-exposure occurs, call your poison control center at 1-800-222-1222 for current information on the management of poisoning or over-exposure.
Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
Participants will attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
Two major QTL for resistance to stripe rust were mapped on chromosome 2BL and 4BL in spring wheat PI 660072, and their KASP markers were developed. Stripe rust, caused by Puccinia striiformis f. sp. tritici (Pst), is one of the most devastating diseases of wheat worldwide. Identifying resistance genes is crucial for developing resistant cultivars to control the disease. Spring wheat PI 660072 (Triticum aestivum) has been identified to possess both adult-plant resistance (APR) and all-stage resistance (ASR) to stripe rust. To elucidate the genetic basis of the resistance in PI 660072, a mapping population consisting of 211 F5-F7 recombinant-inbred lines (RILs) was developed from a cross of PI 660072 with susceptible spring wheat Avocet S. The mapping population was phenotyped for stripe rust responses across five field environments from 2020 to 2022 and genotyped using the 15 K SNP (single nucleotide polymorphism) array to map stripe rust resistance loci. The mapping population was also tested at the seedling stage with predominant Chinese Pst races CYR31, CYR32, CYR34 and PST-YX1-3-1 in the greenhouse. Stripe rust resistance genes were identified using the quantitative trait locus (QTL) mapping approach. Two QTL were identified with QYrPI660072.swust-2BL mapped on the long arm of chromosome 2B for ASR and QYrPI660072.swust-4BL on the long arm of chromosome 4B for APR. To facilitate marker-assisted selection breeding, Kompetitive allele specific PCR (KASP) markers, KASP-1269 for QYrPI660072.swust-2BL and KASP-3209 for QYrPI660072.swust-4BL, were developed. These markers could be used to introgress the effective resistance QTL into new wheat cultivars.
Described are dietary strategies that will produce natural antagonists of arachidonic acid (AA) in inflammatory cells, thereby reducing the synthesis of pro-inflammatory eicosanoids, but without increasing serum levels of AA.  Dietary supplements comprising gammalinoleic acid (GLA) are beneficial in treating inflammatory disease through an increase in neutrophil GLA, but there is a concomitant increase in serum AA.  It has been discovered that neutrophils, the inflammatory response cells, do not possess a -5 desaturase.  Thus, the product of GLA elongation, dihomogammalinoleic acid (DGLA) cannot be converted to AA and eicosanoids.  However, in serum, DGLA formed from the elongation of GLA is converted to AA via the action of a -5 desaturase.  This build-up of serum AA is likely to have harmful consequences in humans.  For example, previous studies have demonstrated that increases in AA of this magnitude can increase platelet reactivity. Increases in sensitivity of platelets to stimuli in most cases are not desirable.  Providing a -5 desaturase inhibitor has circumvented this problem, in this case, eicosapentaenoic acid (EPA) in combination with the GLA, which prevents the serum increase in AA levels upon GLA administration. Thus, there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement and thereby control inflammation.
For patients receiving doses greater than 4 mg/day, periodic reassessment and consideration of dosage reduction is advised. In a controlled postmarketing dose-response study, patients treated with doses of alprazolam greater than 4 mg/day for 3 months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit. Because of the danger of withdrawal, abrupt discontinuation of treatment should be avoided. (See WARNINGS, PRECAUTIONS, DRUG ABUSE AND DEPENDENCE.)

The necessary duration of treatment for panic disorder patients responding to alprazolam is unknown. After a period of extended freedom from attacks, a carefully supervised tapered discontinuation may be attempted, but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena.
Patients who are eligible to participate in the study will receive 3 cycles of sacituzumab govitecan, zimberelimab and domvanalimab every 3 weeks prior to cystectomy, unless there are signs of unacceptable toxicity, progressive disease, or the patient requests withdrawal from the study. Patients who do not achieve a pCR or that achieving a pCR still have positive ctDNA will also complete an adjuvant phase of the study consisting of 12 additional cycles of zimberelimab and domvanalimab after cystectomy.
The present invention relates to an antivirus medicament which is characterized in that the antivirus medicament is prepared from the following raw materials by the following preparation method: alcohol with 3 to 4 times of the quantity of fresh houttuynia is added in the fresh houttuynia for reflux extraction; the time of first reflux extraction is from 3 to 4 hours; the time of second reflux extraction is from 2 to 3 hours; the time of third reflux extraction of reducing the concentration of the alcohol is from 1 to 2 hours; filter liquor of three times are combined and are concentrated into paste until an alcohol taste does not exist for manufacturing a needed preparation. The preparation method of houttuynia medicament is fundamentally different from the existing extraction process. Indicated by years of repeated experimental results, the effective part of the antivirus function of the houttuynia is not in volatile oil and is in an alcohol extract of the non volatile oil part. The antivirus medicament fundamentally changes the existing traditional extraction process and knowledge. A houttuynia alcohol extract is sampled in a mouse of influenza viruses, encephalomyocarditis viruses and herpesvirus infection, and has obvious functions of prevention and protection. Proved by an experiment, the houttuynia alcohol extract is used for resisting viruses and has an obvious therapeutic effect.
The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10\^6 cells/kg, 1.0 x 10\^6 cells/kg, 1.5 x 10\^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10\^6 cells/kg.
The intervention regards education on healthy lifestyles to promote active ageing (topics: physical activity in old age; effective communication, stress management, technologies and health). It will consist of 3 seminars, delivered in the form of webinars, on a bi-weekly basis over 6 consecutive weeks, lasting 50-60 minutes each.
A system predicts the mental state of a user using a variety of contact or contactless sensors that measure heart rate, breathing or other data of the user. The mental state may be flow, overload, underload, stress, attention, motivation, valence, arousal, etc. While performing a game-playing task the difficulty of the task is adjusted based upon the predicted mental state of the user. A classifier for classifying a mental state is trained using event marking and ground truth data. Computer usage generates event markers. Game playing is used to simulate a mental state. Interruptions of a user are prevented when the user enters a flow, focused, or effortful attention state by classifying that state and indicating physically or electronically that the user should not be interrupted. Interruptions of a user are also prevented when the user enters a mind wandering state by classifying or predicting that state and indicating physically or electronically that the user should not be interrupted. A cost of interrupting is calculated and displayed. Users may also be coached regarding mental state. Advertisements to the user may vary based upon a classified mental state of the user.
Materials and Methods: 157 patients who will undergo elective surgery under general anesthesia, ages between 18-80, BMI ≥ 30 kg/m2, ASA I-II were included in the study. During the preoperative evaluation, patients' gender, age, height, weight, type of surgery, BMI, neck circumference, thyromental distance (TMM), sternomental distance (SMM), hyomental distance (HMM), neck extension, mouth opening and distance between incisors were measured and tooth structure was evaluated. OSAS was evaluated based on the ASA physical condition score and AHI. Mallampati Classification was recorded. Upper lip bite test was performed. Ultrasonographic measurements were made with the patient in the supine position and the head and neck in a neutral position. The Han Scale was used to evaluate difficult mask ventilation. The laryngoscopy image was evaluated and recorded with the Cormack-Lehane Classification, and ≥2b was accepted as difficult laryngoscopy.
Extensor muscle endurance, flexor muscle endurance and the lateral core muscle endurance were evaluated. All tests were performed by a chronometer and test was terminated as the position was lost and the time passed was recorded. Hand grip strength was measured by Jamar hand dynamometer. Health ball throwing test was used to evaluate upper extremity open kinetic chain and explosive power. Pro-agility test was used to evaluate the agility. Step test was performed for 3 minutes with a 30 cm high step board.
A four-week period of standard of care dysphagia treatment consisting of physical swallowing-related exercises. According to guidelines for single case design, this standard of care treatment will serve as a baseline/control period for comparison to the subsequent experimental treatment period. Participants will complete either 6, 7, or 8 baseline measurement visits across these 4 weeks (multiple baseline design).
An unblinded, parallel-arm, randomized, controlled clinical trial will be conducted. This phase 2 clinical trial focuses on exploring the effect of the intervention on the study variables.The intervention group will be given access to the ePRO application and proactive clinical care, including study nurses responding to ePROs and weekly health information videos for six months. Participants of the control group will be provided with a list of electronic links to videos on breast cancer-relevant topics on the websites of recognised cancer associations and health institutions. All participants will continue to receive the usual health care provided by the hospital. Study intervention wil last 6 months with additional passive folow-up till 9 months to allow post-intervention monitoring.

The participants will be randomly allocated to the intervention or control groups. The minimization technique with MS-DOS Minim program will be used for randomization. It will be conducted by a research assistant who will use a pre-prepared list of random numbers to randomize the first six participants. Starting with the seventh participant, randomization will be carried out using MS-DOS Minim program. The minimization technique is recommended as a standard to ensure that clinical trial groups are similar in terms of participant characteristics, such as age, schooling, breast cancer stage and treatment modality.

Intervention implementation: The lead researcher will weekly obtain the list of breast cancer patients who have started or will start neoadjuvant or adjuvant treatment with chemotherapy or radiotherapy within two weeks in the oncology hospital. The previously trained nurses will use this list to invite all eligible breast cancer patients to participate in the study. Initially, patients will be invited by telephone calls to attend the hospital or the research unit (located at the same medical center as the oncology hospital) to receive the study-related information and to confirm eligibility. Those who meet the inclusion criteria will be provided with the option to participate and invited to provide informed consent prior to participation. Participants will be provided with a username, password, and access to the intervention or control interface of the responsive ePRO App, and training on its use. All participants will be asked to answer the baseline record of sociodemographic and clinical characteristics and questionnaires to assess study outcomes. Intervention arm participants will be asked to complete the weekly register and will receive weekly WhatsApp reminders. Study nurses will contact patients without two weekly records to encourage adherence to the intervention. Study nurses will be supported by the study oncologist/ oncology resident to ensure adherence to the intervention activities. Additionally, the nurses will be in regular contact with the study team and will record their activities in the corresponding interface of the responsive ePRO App.
1,023,846. Food additives. P. ARLES. Aug. 30, 1963, No. 34368/63. Heading A2B and A2D. An additive for foodstuffs in the form of granules (2-6 mm. diameter) have a core or ascorbic acid and lactose, the core also including agglomerating agents comprising a fatty substance and saccharose, the granules being encased in a water-soluble coating e.g. starch. In an example granules are prepared from 30 parts ascorbic acid, 70 parts lactose, 3 parts castor oil (the fatty agglomerating substance) 6 parts saccharose enclosed in a coating of 41 parts starch. The additive is for use with glutencontaining foodstuffs, particularly products having a cereal base, such as cereals or biscuits; or it can be used as a preservative with foodstuffs, whether of animal or vegetable origin, such as jams, fatty food-substance and sauces, condiments, beers, syrups, sodas, non-alcoholic beverages, frozen eggs, concentrated milk and powdered milk.
Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
FIELD: medicine. SUBSTANCE: method deals with application of new pharmaceutical composition and corresponding method of therapy. New preparation (enalapril, in particular) causes pronounced palliative action upon symptoms and decreases usage of antacid remedies. The present innovation increases the number of preparations of mentioned indication. EFFECT: higher efficiency of application. 5 cl
Introduction: Recently, antimicrobial resistance has received considerable attention. Broad-spectrum antimicrobial agents are recommended as the initial therapy for post-operative intra-abdominal infections. However, at our institution, we have adopted a tactic of initially treating post-operative intra-abdominal complications with relatively narrow-spectrum antimicrobial agents, such as second-generation cephalosporins. In the present study, we aimed to retrospectively analyze the use of antimicrobial agents and the resulting treatment outcomes in patients with intra-abdominal complications after gastrectomy at our facility. Methods: We conducted a retrospective observational study of patients treated with antibiotic agents for intra-abdominal infectious complications after gastrectomy between 2011 and 2021. We determined the proportion of "initial treatment failures" associated with the initial administration of antibiotic agents for post-operative intra-abdominal complications. Results: Post-operative intra-abdominal infections were observed in 29 patients. Broad-spectrum antimicrobial agents were not administered. We successfully treated 19 patients. Initial treatment failure was observed in 10 patients, of whom five experienced failure due to bacterial resistance to the initial antimicrobial agent. All 10 patients who experienced initial treatment failure were discharged after drainage procedures or other treatments. There were no deaths due to post-operative complications. Cefmetazole was used as the initial antimicrobial agent in 27 of the 29 patients. Conclusions: Considering that all patients with post-gastrectomy intra-abdominal infections were successfully treated using relatively narrow-spectrum antimicrobial agents, and initial treatment failure due to antimicrobial-resistant pathogens was 17.2%, the use of narrow-range antimicrobial agents for intra-abdominal infections after gastrectomy can be deemed appropriate.
Bayesian analyses are becoming more popular as a means of analyzing data, yet the Bayesian approach is novel to many members of the broad clinical audience. While Bayesian analyses are foundational to anesthesia pharmacokinetic/pharmacodynamic modeling, they also can be used for analyzing data from clinical trials or observational studies. The traditional null hypothesis significance testing (frequentist) approach uses only the data collected from the current study to make inferences. On the other hand, the Bayesian approach quantifies the external information or expert knowledge and combines the external information with the study data, then makes inference from this combined information. We introduce to the clinical and translational science researcher what it means to do Bayesian statistics, why a researcher would choose to perform their analyses using the Bayesian approach, when it would be advantageous to use a Bayesian instead of a frequentist approach, and how Bayesian analyses and interpretations differ from the more traditional frequentist methods. Throughout this paper, we use various pain- and anesthesia-related examples to highlight the ideas and statistical concepts that should be relatable to other areas of research as well.